Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYHA1813 + HB1801
- Development stage
- Phase 2
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**SYHA1813 + HB1801** is an experimental combination therapy under clinical investigation for advanced solid tumors and potentially other cancers. **SYHA1813** is a potent multikinase inhibitor targeting **vascular endothelial growth factor receptors (VEGFRs)** and **colony-stimulating factor 1 receptor (CSF1R)**, which can inhibit tumor angiogenesis and modulate the tumor microenvironment[1]. **HB1801** is an **albumin-bound formulation of docetaxel** (a chemotherapeutic agent from the taxane family), designed to enhance docetaxel's efficacy and tolerability. This combination leverages both antiangiogenic and cytotoxic mechanisms and is being explored in multi-cohort phase I/II trials for multiple advanced solid tumors[3]. Development is supported by CSPC Pharmaceutical Group, and studies are ongoing in China.
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SYHA1813 + HB1801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYHA1813 + HB1801.